Soleno Therapeutics Inc (SLNO) — Cash Flow-to-Debt Ratio
Soleno Therapeutics Inc (SLNO) has a Cash Flow-to-Debt Ratio of 0.23x as of March 2026, meaning its operating cash flow of $25.98 Million could theoretically repay 0% of its total liabilities ($112.59 Million) in one year. See financial agility of Soleno Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Soleno Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Soleno Therapeutics Inc across 14 annual periods. For the full cash flow conversion analysis, see SLNO cash flow metrics.
Annual Cash Flow-to-Debt Ratio for Soleno Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Soleno Therapeutics Inc. Check SLNO cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.41x | $46.80 Million | $113.72 Million | ▲ +151.1% |
| 2024 | -0.80x | $-69.10 Million | $85.86 Million | ▲ +25.2% |
| 2023 | -1.08x | $-24.94 Million | $23.18 Million | ▲ +16.4% |
| 2022 | -1.29x | $-20.78 Million | $16.15 Million | ▲ +17.7% |
| 2021 | -1.56x | $-27.77 Million | $17.76 Million | ▼ -20.5% |
| 2020 | -1.30x | $-25.22 Million | $19.43 Million | ▼ -73.5% |
| 2019 | -0.75x | $-17.38 Million | $23.23 Million | ▲ +18.4% |
| 2018 | -0.92x | $-11.68 Million | $12.74 Million | ▼ -15.1% |
| 2017 | -0.80x | $-9.95 Million | $12.49 Million | ▲ +87.4% |
| 2016 | -6.34x | $-13.50 Million | $2.13 Million | ▼ -206.3% |
| 2015 | -2.07x | $-10.30 Million | $4.98 Million | ▼ -764.2% |
| 2014 | -0.24x | $-4.48 Million | $18.73 Million | ▼ -967.1% |
| 2013 | -0.02x | $-885.22K | $39.45 Million | ▲ +76.4% |
| 2012 | -0.10x | $-3.50 Million | $36.71 Million | — |